Aktienanalyse zu ICON PLC (ICLR)ICLRICON PLC

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals. It operates in the Healthcare sector (COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH industry).

ICON PLC (ICLR) appears to be a good buy right now, trading at $170.18 with a forward P/E of 14.75, indicating potential for growth compared to its current valuation. The recent positive earnings surprise of 2.78% and a 5-day price increase of 3.66% suggest upward momentum. However, the main risk is the company's declining net margin, which fell to 3.52% in Q2 2026 from 10.66% in Q4 2024, indicating potential profitability challenges ahead.

15 analysts cover ICLR: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 202.67.